Intracellular delivery system for antibody-peptide drug conjugates

Molecular Therapy

Volumn 23, Issue 5, 2015, Pages 907-917

  Berguig, Geoffrey Y ^a,d   Convertine, Anthony J ^a   Frayo, Shani ^b   Kern, Hanna B ^a   Procko, Erik ^c,f   Roy, Debashish ^a   Srinivasan, Selvi ^a   Margineantu, Daciana H ^b   Booth, Garrett ^b   Palanca Wessels, Maria Corinna ^b,e   Baker, David ^c   Hockenbery, David ^b   Press, Oliver W ^b   Stayton, Patrick S ^a  

^a University of Washington   (United States)

^b USA   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^d BIOMARIN PHARMACEUTICAL INC   (United States)

^e SEATTLE GENETICS INC   (United States)

^f UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY PEPTIDE CONJUGATE; ANTINEOPLASTIC AGENT; CASPASE 3; CD22 ANTIBODY BIM PROTEIN CONJUGATE; COPOLYMER; CYTOCHROME C; KI 67 ANTIGEN; POLYPEPTIDE; PROTEIN BCL 2; UNCLASSIFIED DRUG; ANTIBODY CONJUGATE; BIOLOGICAL MARKER; MICELLE; MONOCLONAL ANTIBODY; PEPTIDE; POLYMER;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; B CELL LYMPHOMA; CANCER INHIBITION; CANCER SURVIVAL; CELL ASSAY; CELL POPULATION; CONTROLLED STUDY; DISEASE MARKER; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG OVERDOSE; DRUG STRUCTURE; ENZYME MODIFICATION; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LOW DRUG DOSE; MICELLE; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PH MEASUREMENT; PLASMA CLEARANCE; PROTEIN CLEAVAGE; PROTEIN SECRETION; SURVIVAL RATE; SURVIVAL TIME; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR XENOGRAFT; ANIMAL; APOPTOSIS; BIOAVAILABILITY; BIOSYNTHESIS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; DRUG STABILITY; LYMPHOMA, B-CELL; METABOLISM; MORTALITY; PATHOLOGY; TISSUE DISTRIBUTION; TUMOR CELL LINE; TUMOR VOLUME;

ANIMALS; ANTIBODIES, MONOCLONAL; APOPTOSIS; BIOLOGICAL AVAILABILITY; BIOMARKERS; CELL LINE, TUMOR; CYTOCHROMES C; DISEASE MODELS, ANIMAL; DRUG DELIVERY SYSTEMS; DRUG STABILITY; HUMANS; IMMUNOCONJUGATES; LYMPHOMA, B-CELL; MICE; MICELLES; PEPTIDES; POLYMERS; PROTO-ONCOGENE PROTEINS C-BCL-2; TISSUE DISTRIBUTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84929044110     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.22     Document Type: Article

References (48)

1. Senter PD. (2009). Potent antibody drug conjugates for cancer therapy. Curr Opin Chem Biol 13: 235-244
2. Ricart AD. (2011). Immunoconjugates against solid tumors: mind the gap. Clin Pharmacol Ther 89: 513-523
3. Johannes L and Decaudin D. (2005). Protein toxins: intracellular trafficking for targeted therapy. Gene Ther 12: 1360-1368
4. Susnow N, Zeng L, Margineantu D and Hockenbery DM. (2009). Bcl-2 family proteins as regulators of oxidative stress. Semin Cancer Biol 19: 42-49
5. Lessene G, Czabotar PE and Colman PM. (2008). BCL-2 family antagonists for cancer therapy. Nat Rev Drug Discov 7: 989-1000
6. Ni Chonghaile T, Sarosiek KA, Vo, TT, Ryan JA, Tammareddi A, Moore Vdel G, et al. (2011). Pretreatment mitochondrial priming correlates with clinical response to cytotoxic chemotherapy. Science 334: 1129-1133
7. Liu G, Kelly WK, Wilding G, Leopold L, Brill K and Somer B. (2009). An open-label multicenter phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer. Clin Cancer Res 15: 3172-3176
8. O'Brien SM, Claxton DF, Crump M, Faderl S, Kipps T, Keating MJ, et al. (2009). Phase I study of obatoclax mesylate (GX15-070), a small molecule pan-Bcl-2 family antagonist in patients with advanced chronic lymphocytic leukemia. Blood 113: 299-305
9. Rudin CM, Hann CL, Garon EB, Ribeiro De Oliveira M, Bonomi PD, Camidge DR, et al. (2012). Phase II study of single-agent navitoclax (ABT-263) and biomarker correlates in patients with relapsed small cell lung cancer. Clin Cancer Res 18: 3163-3169
10. Thomas S, Quinn BA, Das SK, Dash R, Emdad L, Dasgupta S, et al. (2013). Targeting the Bcl-2 family for cancer therapy. Expert Opin Ther Targets 17: 61-75
11. Yecies D, Carlson NE, Deng J and Letai A. (2010). Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1. Blood 115: 3304-3313
12. Mason KD, Vandenberg CJ, Scott CL, Wei AH, Cory S, Huang DC, et al. (2008). In vivo efficacy of the Bcl-2 antagonist ABT-737 against aggressive Myc-driven lymphomas. Proc Natl Acad Sci USA 105: 17961-17966
13. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S and Korsmeyer SJ. (2002). Distinct BH3 domains either sensitize or activate mitochondrial apoptosis serving as prototype cancer therapeutics. Cancer Cell 2: 183-192
14. Certo M, Del Gaizo Moore V, Nishino M, Wei G, Korsmeyer S, Armstrong SA, et al. (2006). Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members. Cancer Cell 9: 351-365
15. LaBelle JL, Katz SG, Bird GH, Gavathiotis E, Stewart ML, Lawrence C, et al. (2012). A stapled BIM peptide overcomes apoptotic resistance in hematologic cancers. J Clin Invest 122: 2018-2031
16. Kashiwagi H, McDunn JE, Goedegebuure PS, Gaffney MC, Chang K, Trinkaus K, et al. (2007). TAT-Bim induces extensive apoptosis in cancer cells. Ann Surg Oncol 14: 1763-1771
17. Berguig GY, Convertine AJ, Shi J, Palanca-Wessels MC, Duvall CL, Pun SH, et al. (2012). Intracellular delivery and trafficking dynamics of a lymphoma-targeting antibody-polymer conjugate. Mol Pharm 9: 3506-3514
18. Palanca-Wessels MC, Convertine AJ, Cutler-Strom R, Booth GC, Lee F, Berguig GY, et al. (2009). Anti-CD22 antibody targeting of pH-responsive micelles enhances small interfering RNA delivery and gene silencing in lymphoma cells. 19: 1-9
19. Duvall CL, Convertine AJ, Benoit DS, Hoffman AS and Stayton PS. (2010). Intracellular delivery of a proapoptotic peptide via conjugation to a RAFT synthesized endosomolytic polymer. Mol Pharm 7: 468-476
20. Wilson JT, Keller S, Manganiello MJ, Cheng C, Lee CC, Opara C, et al. (2013). pH- Responsive nanoparticle vaccines for dual-delivery of antigens and immunostimulatory oligonucleotides. ACS Nano 7: 3912-3925
21. Manganiello MJ, Cheng C, Convertine AJ, Bryers JD and Stayton PS. (2012). Diblock copolymers with tunable pH transitions for gene delivery. Biomaterials 33: 2301-2309
22. Cheng C, Convertine AJ, Stayton PS and Bryers JD. (2012). Multifunctional triblock copolymers for intracellular messenger RNA delivery. Biomaterials 33: 6868-6876
23. Huang C, Neoh KG, Xu, L, Kang ET and Chiong E. (2012). Polymeric nanoparticles with encapsulated superparamagnetic iron oxide and conjugated cisplatin for potential bladder cancer therapy. Biomacromolecules 13: 2513-2520
24. Jiang X, Vogel EB, Smith MR and Baker GL. (2008). 'Clickable' polyglycolides: tunable synthons for thermoresponsive degradable polymers. Macromolecules 41: 1937-1944
25. Lutz J-F. (2008). Polymerization of oligo(ethylene glycol) (meth)acrylates: toward new generations of smart biocompatible materials. J Polym Sci A Polym Chem 46: 3459-3470
26. Roy D, Berguig GY, Ghosn B, Lane D, Braswell S, Stayton PS, et al. (2014). Synthesis and characterization of transferrin-targeted chemotherapeutic delivery systems prepared via RAFT copolymerization of high molecular weight PEG macromonomers. Polym Chem 5: 1791-1799
27. El-Sayed ME, Hoffman AS and Stayton PS. (2005). Rational design of composition and activity correlations for pH-sensitive and glutathione-reactive polymer therapeutics. J Control Release 101: 47-58
28. Convertine AJ, Benoit DS, Duvall CL, Hoffman AS and Stayton PS. (2009). Development of a novel endosomolytic diblock copolymer for siRNA delivery. J Control Release 133: 221-229
29. Convertine AJ, Diab C, Prieve M, Paschal A, Hoffman AS, Johnson PH, et al. (2010). pH-responsive polymeric micelle carriers for siRNA drugs. Biomacromolecules 11: 2904-2911
30. Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, et al. (2007). Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood 109: 4980-4987
31. Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, et al. (2007). Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res 67: 5921-5928
32. Nishiyama N, Kato Y, Sugiyama Y and Kataoka K. (2001). Cisplatin-loaded polymermetal complex micelle with time-modulated decaying property as a novel drug delivery system. Pharm Res 18: 1035-1041
33. Bae Y, Nishiyama N, Fukushima S, Koyama H, Yasuhiro M and Kataoka K. (2005). Preparation and biological characterization of polymeric micelle drug carriers with intracellular pH-triggered drug release property: tumor permeability controlled subcellular drug distribution and enhanced in vivo antitumor efficacy. Bioconjug Chem 16: 122-130
34. Gu, F, Zhang L, Teply BA, Mann N, Wang A, Radovic-Moreno AF, et al. (2008). Precise engineering of targeted nanoparticles by using self-assembled biointegrated block copolymers. Proc Natl Acad Sci USA 105: 2586-2591
35. Cheng J, Teply BA, Sherifi I, Sung J, Luther G, Gu, FX, et al. (2007). Formulation of functionalized PLGA-PEG nanoparticles for in vivo targeted drug delivery. Biomaterials 28: 869-876
36. Habel ME and Jung D. (2006). c-Myc over-expression in Ramos Burkitt's lymphoma cell line predisposes to iron homeostasis disruption in vitro. Biochem Biophys Res Commun 341: 1309-1316
37. Campone M, Noël B, Couriaud C, Grau M, Guillemin Y, Gautier F, et al. (2011). c-Myc dependent expression of pro-apoptotic Bim renders HER2-overexpressing breast cancer cells dependent on anti-apoptotic Mcl-1. Mol Cancer 10: 110
38. Demidenko E. (2010). Three endpoints of in vivo tumour radiobiology and their statistical estimation. Int J Radiat Biol 86: 164-173
39. Heitjan DF, Manni A and Santen RJ. (1993). Statistical analysis of in vivo tumor growth experiments. Cancer Res 53: 6042-6050
40. Chiefari J, Chong YK, Ercole F and Krstina J. (1998). Living free-radical polymerization by reversible addition-fragmentation chain transfer: the RAFT process. Macromolecules 31: 5559-5562
41. Moad G, Chiefari J and Krstina J. (2000). Living free radical polymerization with reversible addition-fragmentation chain transfer (the life of RAFT). Polym Int 49: 993-1001
42. Convertine AJ, Ayres N, Scales CW, Lowe AB and McCormick CL. (2004). Facile controlled room-temperature RAFT polymerization of N-isopropylacrylamide. Biomacromolecules 5: 1177-1180
43. Klasa RJ, Bally MB, Ng, R, Goldie JH, Gascoyne RD and Wong FM. (2000). Eradication of human non-Hodgkin's lymphoma in SCID mice by BCL-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res 6: 2492-2500
44. Vandenberg CJ and Cory S. (2013). ABT-199, a new Bcl-2-specific BH3 mimetic has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. Blood 121: 2285-2288
45. Förster GJ, Santos EB, Smith-Jones PM, Zanzonico P and Larson SM. (2006). Pretargeted radioimmunotherapy with a single-chain antibody/streptavidin construct and radiolabeled DOTA-biotin: strategies for reduction of the renal dose. J Nucl Med 47: 140-149
46. Wilbur DS, Park SI, Chyan MK, Wan F, Hamlin DK, Shenoi J, et al. (2010). Design and synthesis of bis-biotin-containing reagents for applications utilizing monoclonal antibody-based pretargeting systems with streptavidin mutants. Bioconjug Chem 21: 1225-1238
47. Hylarides MD, Mallett RW and Meyer DL. (2001). A robust method for the preparation and purification of antibody/streptavidin conjugates. Bioconjug Chem 12: 421-427
48. Murthy N, Campbell J, Fausto N, Hoffman AS and Stayton PS. (2003). Design and synthesis of pH-responsive polymeric carriers that target uptake and enhance the intracellular delivery of oligonucleotides. J Control Release 89: 365-374